Published: Jan. 1, 2024
Language: Английский
Published: Jan. 1, 2024
Language: Английский
International Journal of Pharmaceutics, Journal Year: 2024, Volume and Issue: unknown, P. 124869 - 124869
Published: Oct. 1, 2024
Language: Английский
Citations
4Journal of Molecular Liquids, Journal Year: 2024, Volume and Issue: unknown, P. 126541 - 126541
Published: Nov. 1, 2024
Language: Английский
Citations
4npj Vaccines, Journal Year: 2025, Volume and Issue: 10(1)
Published: Jan. 3, 2025
Language: Английский
Citations
0International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: unknown, P. 125247 - 125247
Published: Jan. 1, 2025
Language: Английский
Citations
0Small, Journal Year: 2025, Volume and Issue: unknown
Published: March 27, 2025
Proteins are typically subject to poor stability, short half-life, and cell tissue permeability, which restrict their wide applications as drugs for disease treatment. Current protein modification techniques mostly focus on improving the stability half-life of proteins, but hardly solve permeability. To address this issue, study innovatively designs thermo-pH-sensitive elastin-like polypeptides modify named ELP(HX)n in histidine (H) any amino acid except proline (X) guest acids n is total number acids. H can be protonated under acidic conditions. prove concept, an important drug L-asparaginase (ASP) genetically fused ELP(HV)60 generate ASP-ELP(HV)60. Compared with ASP PEGylated ASP, ASP-ELP(HV)60 exhibits not only elevated extended also enhanced tumor penetration, resulting improved antitumor efficacy. These findings demonstrate that fusion a novel general method overcome intrinsic limitations proteins therapeutics, rendering it feasible design intelligent especially efficient therapy.
Language: Английский
Citations
0Journal of Drug Delivery Science and Technology, Journal Year: 2025, Volume and Issue: unknown, P. 106947 - 106947
Published: April 1, 2025
Language: Английский
Citations
0Acta Biomaterialia, Journal Year: 2024, Volume and Issue: 189, P. 25 - 56
Published: Sept. 20, 2024
Language: Английский
Citations
3Journal of Molecular Structure, Journal Year: 2024, Volume and Issue: 1315, P. 138618 - 138618
Published: May 14, 2024
Language: Английский
Citations
2AAPS PharmSciTech, Journal Year: 2024, Volume and Issue: 25(7)
Published: Sept. 5, 2024
Language: Английский
Citations
2Published: June 20, 2024
Nanovaccines are able to deliver antigen(s) and immunomodulator(s) directly antigen-presenting cells (APCs) of the lymphatic system. Positive charges improve their uptake by APCs often drive a Th-1 biased immune response so necessary against infectious diseases caused intracellular pathogens cancers. However, cationic compounds display dose-dependent toxicity that systematic evaluation cytotoxicity in culture is required. After rapid evolution nanovaccines SARS-Covid 2, mRNA vaccines gained much strength have been designed several diseases, relying on components for protection. Once established limiting concentration compound, perform well eliciting desired improved most cases. Other valuable approach found literature has construction biocompatible nanoparticles (NPs) carrying lipids, polymers or surfactants minimization component led absence toxicity. Against cancer, recent constructions situ after cancer cell disruption presence adjuvants systemic presentation multiple tumoral antigens yielding, many instances, prevention metastasis appearance conversion tumors non treatable immunotherapy into ones.
Language: Английский
Citations
1